Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1653 1671
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18151174 | NIPAH VIRUS ENVELOPE PSEUDOTYPED LENTIVIRUSES AND METHODS OF THEIR USE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18022056 | ADENO-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED EXPRESSION LEVELS | Non-Final OA | California Institute of Technology |
| 17412900 | Stable Reporter Flavivirus | Non-Final OA | Board of Regents, the University of Texas System |
| 17296829 | T Cell-Directed Anti-Cancer Vaccines Against Commensal Viruses | Non-Final OA | The General Hospital Corporation |
| 17919997 | COMPOSITIONS AND METHODS FOR FORMATION AND SECRETION OF EXTRACELLULAR VESICLES AND AAV PARTICLES | Non-Final OA | DUKE UNIVERSITY |
| 17791981 | SYSTEM AND METHOD FOR PROCESSING VIRUS PREPARATIONS TO REDUCE HETEROGENEITY | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 17393824 | METHODS AND KITS FOR DETECTING SARS-COV-2 PROTEIN IN A SAMPLE | Final Rejection | Abbott Laboratories |
| 17911367 | KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18817094 | Rhinovirus Vaccine | Non-Final OA | IP2IPO INNOVATIONS LIMITED |
| 18345478 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Non-Final OA | The United States of America, As Represented by the Secretary, Dept. of Health and Human Services |
| 17919065 | ADENOVIRUS IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT | Final Rejection | Denka Company Limited |
| 18548708 | CAPILLARY ELECTROPHORESIS METHODS FOR QUANTIFYING VIRAL SPECIES | Non-Final OA | DH Technologies Development Pte. Ltd. |
| 17767532 | PRODUCTION METHOD AND DETECTION METHOD OF AFRICAN SWINE FEVER VIRUS | Final Rejection | National Agriculture and Food Research Organization |
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | Non-Final OA | TAKEDA VACCINES, INC. |
| 17274016 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | Final Rejection | Takeda Vaccines, Inc. |
| 17633063 | CELLULAR COMPOSITIONS COMPRISING VIRAL VECTORS AND METHODS OF TREATMENT | Final Rejection | Mesoblast International Sárl |
| 18011742 | METHOD FOR PREPARING ADENOVIRUS VECTOR VACCINE BY MEANS OF PERFUSION CULTURE PROCESS | Non-Final OA | CANSINO BIOLOGICS INC. |
| 18007823 | ENHANCED PURIFICATION OF ADENO-ASSOCIATED VIRUS TO MORE EFFECTIVELY REMOVE CONTAMINATING DNA | Non-Final OA | Sartorius BIA Separations d.o.o. |
| 17800592 | A METHOD FOR SEPARATION OR DEPLETION OF EMPTY AAV CAPSIDS FROM FULL AAV CAPSIDS | Non-Final OA | Sartorius BIA Separations d.o.o. |
| 18058403 | ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2 | Non-Final OA | ARABIAN GULF UNIVERSITY |
| 17948868 | DUAL BIFUNCTIONAL VECTORS FOR AAV PRODUCTION | Final Rejection | uniQure biopharma B.V. |
| 17736181 | ENGINEERED BACTERIOPHAGE T4 NANOPARTICLES AS A POTENTIAL TARGETED ACTIVATOR OF HIV-1 LATENCY IN CD4+ HUMAN T-CELLS | Final Rejection | The Catholic University of America |
| 17627162 | USE OF ION CONCENTRATIONS TO INCREASE THE PACKAGING EFFICIENCY OF RECOMBINANT ADENO-ASSOCIATED VIRUS | Final Rejection | CHARLES RIVER LABORATORIES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy